JP Morgan Chase’s Acadia Pharmaceuticals ACAD Stock Holding History

JP Morgan Chase’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,000	Closed	-$415K	–	7362
2024 Q3	$415K	Hold	27,000	–	–	﹤0.01%	5022
2024 Q2	$439K	Buy	27,000 +19,300	+251%	+$311K	﹤0.01%	4760
2024 Q1	$142K	Buy	+7,700	New	+$191K	﹤0.01%	5518
2023 Q4	–	Sell	-192,000	Closed	-$4M	–	7483
2023 Q3	$4M	Buy	+192,000	New	+$5.21M	﹤0.01%	2997
2022 Q3	–	Sell	-102,700	Closed	-$1.45M	–	6418
2022 Q2	$1.45M	Buy	+102,700	New	+$1.92M	﹤0.01%	3818
2021 Q2	–	Sell	-10,500	Closed	-$271K	–	6304
2021 Q1	$271K	Hold	10,500	–	–	﹤0.01%	5020
2020 Q4	$561K	Buy	+10,500	New	+$521K	﹤0.01%	4304
2020 Q1	–	Sell	-74,100	Closed	-$3.17M	–	5240
2019 Q4	$3.17M	Buy	+74,100	New	+$3.22M	﹤0.01%	3048

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase's ACAD Position: Q1 2026 in Review

JP Morgan Chase reduced its Acadia Pharmaceuticals (ACAD) stake by 2.9% in Q1 2026, selling an estimated $185K and leaving 263,091 shares worth $5.54M. The position accounts for ﹤0.01% of the portfolio, ranked #3233.

JP Morgan Chase first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $72.1M in Q3 2017. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

JP Morgan Chase held 263,091 shares of Acadia Pharmaceuticals worth $5.54M as of Q1 2026.
JP Morgan Chase sold 7,735 Acadia Pharmaceuticals shares in Q1 2026, an estimated $185K.
Acadia Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3233 holding.
JP Morgan Chase first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
JP Morgan Chase's Acadia Pharmaceuticals position peaked at $72.1M in Q3 2017.
341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.